Clinical trial

RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer

NCT07269691

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-12-01

PhasePHASE3

Study timeline

Study start (estimated)2025-12-01Date precision: day

Registry last updated2025-12-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancer Early Stage Breast Cancer (Stage 1-3)unresolved

Breast Cancerunresolved

Interventions

Iodine-125 Radioactive Seed MarkingDEVICE

Standard Neoadjuvant TherapyDRUG

Sponsors & collaborators

Pengfei Qiulead sponsor

Mapped research locations

JinanShandong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07269691 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.